MarketCap
Facebook
X
Telegram
QIAGEN N.V. Operating Income | QGEN
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income QIAGEN N.V.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 466 M | 97.7 M | 410 M | 531 M | 630 M | 386 M | -26.1 M | 267 M | 153 M | 98.8 M | 179 M | 162 M | 63.3 M | 170 M | 99.6 M | 189 M | 180 M | 146 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 630 M | -26.1 M | 233 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K |  USA |
 |
Biomerica
BMRA
|
-5.32 M | $ 1.69 | 0.6 % | $ 4.93 M | USA |
 |
Myriad Genetics
MYGN
|
-387 M | $ 6.03 | 3.52 % | $ 558 M | USA |
 |
Pacific Biosciences of California
PACB
|
-554 M | $ 2.25 | 6.64 % | $ 675 M | USA |
 |
Neuronetics
STIM
|
-31.4 M | $ 2.26 | 7.11 % | $ 149 M | USA |
 |
Agilent Technologies
A
|
1.48 B | $ 175.77 | 1.56 % | $ 49.9 B | USA |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 357.54 | 3.52 % | $ 17.7 B | USA |
 |
Fulgent Genetics
FLGT
|
-91.1 M | $ 20.23 | 0.65 % | $ 623 M | USA |
 |
Guardant Health
GH
|
-437 M | $ 173.31 | 2.5 % | $ 21.7 B | USA |
 |
Accelerate Diagnostics
AXDX
|
-35.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 328.03 | -0.28 % | $ 27.3 B | USA |
 |
Lantheus Holdings
LNTH
|
311 M | $ 99.94 | 0.14 % | $ 6.74 B | USA |
 |
ENDRA Life Sciences
NDRA
|
-5.76 M | $ 4.82 | 0.42 % | $ 3.79 M | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 16.7 | 0.63 % | $ 2.14 B | USA |
 |
Neogen Corporation
NEOG
|
-21.6 M | $ 12.22 | 0.21 % | $ 2.66 B | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 22.54 | 2.78 % | $ 505 M | USA |
 |
Natera
NTRA
|
-310 M | $ 404.77 | 0.2 % | $ 55.3 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
-54.8 M | $ 11.74 | -0.68 % | $ 123 M |  China |
 |
OPKO Health
OPK
|
-117 M | $ 1.63 | 1.23 % | $ 1.22 B | USA |
 |
Trinity Biotech plc
TRIB
|
-21.2 M | $ 7.3 | -0.06 % | $ 2.62 B |  Irlanda |
 |
T2 Biosystems
TTOO
|
-49.7 M | - | -39.35 % | $ 313 K | USA |
 |
Bioventus
BVS
|
54 M | $ 14.75 | -1.44 % | $ 983 M | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Precipio
PRPO
|
-1.2 M | $ 19.5 | -2.55 % | $ 31.3 M | USA |
 |
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
RadNet
RDNT
|
62 M | $ 69.9 | -0.63 % | $ 5.26 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
1.42 B | $ 26.55 | -1.28 % | $ 25.2 B |  Niderland |
 |
Senseonics Holdings
SENS
|
-68.3 M | $ 7.46 | -0.67 % | $ 311 M | USA |
 |
Sotera Health Company
SHC
|
298 M | $ 18.35 | 1.35 % | $ 5.21 B | USA |
 |
Thermo Fisher Scientific
TMO
|
7.75 B | $ 684.39 | 1.57 % | $ 258 B | USA |
 |
Twist Bioscience Corporation
TWST
|
-136 M | $ 145.39 | 3.91 % | $ 8.7 B | USA |
 |
Celcuity
CELC
|
-172 M | $ 65.75 | 0.76 % | $ 3.07 B | USA |
 |
VolitionRx Limited
VNRX
|
-21.7 M | $ 0.18 | 0.83 % | $ 22.6 M |  Singapore |
 |
Waters Corporation
WAT
|
271 M | $ 456.36 | 0.39 % | $ 27.2 B | USA |
 |
Exagen
XGN
|
-14.1 M | $ 7.44 | 2.34 % | $ 160 M | USA |
 |
Quotient Limited
QTNT
|
-104 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
-5.64 M | - | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
-94.9 M | - | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
403 M | - | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K |  Israel |
 |
Castle Biosciences
CSTL
|
-42.8 M | $ 32.84 | -0.73 % | $ 952 M | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Renalytix AI plc
RNLX
|
-29.6 M | - | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
-1.89 M | - | -1.84 % | $ 15.3 M | USA |
 |
Meridian Bioscience
VIVO
|
54.4 M | - | - | $ 1.49 B | USA |